Treatment recommendations for cerebral venous thrombosis (CVT) include parenteral administration followed by oral anticoagulants in the absence of contraindications. Often, the safety and efficacy data of direct oral anticoagulants (DOACs) in treating venous thromboembolism (VTE) is extrapolated to treat CVT patients. Since the pathological mechanism behind the VTE and CVT are different, it’s essential to carry out separate studies on the effect of DOACs in CVT cohorts.
A randomized controlled trial has demonstrated a DOAC called dabigatran to be as effective as warfarin in treating CVT. Recently, another large multicenter trial has revealed the safety and efficacy of DOACs in treating CVT and was not inferior to warfarin in treating CVT. Study details Key findings Both DOAC group and warfarin group showed the following: Similar recurrent venous thrombosis risk with HR 0.94, 95%CI…
